Deacons advises Modern Chinese Medicine Group Co., Ltd. in relation to its Main Board IPO, seeking to raise up to HK$220.5 million (subject to the exercise of over-allotment option).
Modern Chinese Medicine Group is principally engaged in the production of proprietary Chinese medicine. In particular, it offers both over-the-counter and prescribed medicines intended for use by the middle-aged and the elderly in the PRC.
The company published its IPO prospectus on 31 December 2020. Dealings in its shares on the Main Board of the Hong Kong Stock Exchange are expected to commence on 15 January 2021.
Our team is led by Alexander Que, Partner of our Corporate Finance Practice Group.